Suppression of indoleamine-2,3-dioxygenase 1 expression by promoter hypermethylation in ER-positive breast cancer.
Dewi DL, Mohapatra SR, Blanco Cabañes S, Adam I, Somarribas Patterson LF, Berdel B, Kahloon M, Thürmann L, Loth S, Heilmann K, Weichenhan D, Mücke O, Heiland I, Wimberger P, Kuhlmann JD, Kellner KH, Schott S, Plass C, Platten M, Gerhäuser C, Trump S, Opitz CA.
Dewi DL, et al. Among authors: kahloon m.
Oncoimmunology. 2017 Jan 3;6(2):e1274477. doi: 10.1080/2162402X.2016.1274477. eCollection 2017.
Oncoimmunology. 2017.
PMID: 28344890
Free PMC article.